Pfizer and BioNTech said their Covid-19 vaccine remained 100% effective in children 12 to 15 years old, four months after the second dose.
The companies said that the new data, which involved 2,228 trial participants, will help support their applications for full approval in the United States and worldwide.
No serious safety concerns were observed in individuals with at least six months of follow-up after the second dose. "As the global health community works to increase the number of vaccinated people around the world, these additional data provide further confidence in our vaccine's safety and effectiveness profile in adolescents," said Pfizer CEO Albert Bourla in a statement. "This is especially important as we see rates of Covid-19